Intraindividual Comparison of Gadobenate Dimeglumine and Gadobutrol for Cerebral Magnetic Resonance Perfusion Imaging at 1.5 T

Abstract

Both the 1 molar MR contrast agent gadobutrol and the weak protein-interacting agent gadobenate dimeglumine permit the acquisition of high-quality perfusion maps at doses of 0.1 mmol/kg bw. The susceptibility effect is comparable for both agents and stronger than for conventional MR contrast agents.

A Serial Dilution Study of Gadolinium-Based MR Imaging Contrast Agents

“…These data help explain the potential clinical benefits of higher relaxivity agents and confirm the results seen in the human in vivo crossover trials already reported. [12][13][14][15] These results also support the prediction that higher R2 values would provide similar advantages over lower R2 relaxivity agents for PWI per administered dose/volume of GBMCA and would yield higher CNR and/or shorter scanning times for similar diagnostic CNR end points.…”

“…[7][8][9][10] In clinical trials, it has been found to confer greater conspicuity and detectability to lesions within the central nervous system and associated cerebral vasculature, among other reported benefits. [11][12][13][14][15][16] However, even in the intraindividual crossover studies, biodistribution of contrast within each patient, therefore the local concentration of contrast, cannot be determined or controlled. This was of particular interest, given the slightly different biodistribution reported for gadobenate relative to the other agents, with 3%-5% of the administered gadobenate dose undergoing biliary clearance.…”

Diagnostic Yield of Double-Dose Gadobutrol in the Detection of Brain Metastasis: Intraindividual Comparison with Double-Dose Gadopentetate Dimeglumine

“…[26][27][28] These articles reported increased diagnostic accuracy and the stable chemical and pharmacologic properties of gadobutrol, which are safer than those of previously used agents. For gadobutrol, only half the amount of the previously used 0.5-mol/L Gd contrast agents at the same concentration is enough.…”

MR Imaging of Neoplastic Central Nervous System Lesions: Review and Recommendations for Current Practice

“…[90][91][92] Numerous intraindividual trials have directly compared the imaging characteristics of contrast media in patients with primary CNS lesions or metastases. 91,[93][94][95][96][97][98][99][100][101][102][103][104] Among these trials, gadobenate dimeglumine has demonstrated superior lesion enhancement and diagnostic information compared with gadopentetate or gadodiamide, 99,100,102 which is attributed to the higher relaxivity of gadobenate. In similarly designed trials, gadobutrol has demonstrated superior performance, including enhanced lesion detection and conspicuity, compared with the 0.5-mol/L agents gadopentetate and gadoterate, administered at the same dose and by using the same field strength (1.5T), reflecting the high T1 shortening effect of gadobutrol (Fig 10).…”

“…4,10,[109][110][111][112][113][114][115][116][117][118][119] Double dosing also improves image quality and data quantitation in MR perfusion studies. 95 Typically, as for all pharmaceuticals, the lowest dose possible should be used. This is particularly important in the context of the risk of nephrogenic systemic fibrosis and especially in patients with severely impaired renal function (GFR below 30 mL/min/1.73 m 2 ).…”